Genetically heterogeneous origins of idiopathic erythrocytosis

Hematology

Volumn 12, Issue 2, 2007, Pages 131-139

  Percy, Melanie J ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Erythropoietin; Erythropoietin receptor; Hypoxia inducible factor; Idiopathic erythrocytosis; Prolyl hydroxylase; Von Hippel Lindau protein

Indexed keywords

ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERLEUKIN 3; INTERLEUKIN 6; JANUS KINASE 2; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; THROMBOPOIETIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CELL LINEAGE; ENDEMIC DISEASE; ERYTHROCYTOSIS; ETHNICITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GRANULOCYTE; HEMATOCRIT; HUMAN; IDIOPATHIC DISEASE; LINKAGE ANALYSIS; MEGAKARYOCYTE; MORTALITY; OXYGEN SENSING; PATHOGENESIS; PRECANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANOXEMIA; DIMERIZATION; ERYTHROCYTE VOLUME; ERYTHROPOIESIS; ERYTHROPOIETIN; FEEDBACK, BIOCHEMICAL; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GENOTYPE; HUMANS; HYDROXYLATION; HYPOXIA-INDUCIBLE FACTOR 1; KIDNEY; MODELS, BIOLOGICAL; MUTATION; OXYGEN; POLYCYTHEMIA; PROCOLLAGEN-PROLINE DIOXYGENASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN INTERACTION MAPPING; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; UBIQUITIN; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 34247212833     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330601111979     Document Type: Article

References (87)

1. McMullin, MF, Bareford, D., Campbell, P., Green, AR, Harrison, C., Hunt, B., Oscier, D., Polkey, MI, Reilly, JT, Rosenthal, E., Ryan, K., Pearson, TC and Wilkins, B. (2005) Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol, 130, pp. 174-195.
2. Percy, MJ, Jones, FGC, Lappin, TRJ and McMullin, MF (2005) Mutations in the VHL gene are the major identified cause of inherited erythrocytosis. Blood, 106, p. 169a.
3. 2 tension. Proc Natl Acad Sci U S A., 92, pp. 5510-5514.
4. Blanchard, KL, Acquaviva, AM, Galson, DL and Bunn, HF (1992) Hypoxic induction of the human erythropoietin gene: Cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol, 12, pp. 5373-5385.
5. Semenza, GL (2001) Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology. Trends Mol Med, 7, pp. 345-350.
6. Ratcliffe, PJ (2002) From erythropoietin to oxygen: Hypoxia-inducible factor hydroxylases and the hypoxia signal pathway. Blood Purif, 20, pp. 445-450.
7. Card, PB, Erbel, PJ and Gardner, KH (2005) Structural basis of ARNT PAS-B dimerization: Use of a common beta sheet interface for hetero-homodimerization. J Mol Biol, 353, pp. 664-677.
8. Epstein, AC, Gleadle, JM, McNeill, LA, Hewitson, KS, O'Rourke, J., Mole, DR, Mukherji, M., Metzen, E., Wilson, MI, Dhanda, A., Tian, YM, Masson, N., Hamilton, DL, Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, PH, Pugh, CW, Schofield, CJ and Ratcliffe, PJC (2001) Elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107, pp. 43-54.
9. Bruick, RK and McKnight, SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 294, pp. 1337-1340.
10. Ivan, M., Haberberger, T., Gervasi, DC, Michelson, KS, Gunzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, RC, Conaway, JW and Kaelin Jr, WG (2002) Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A, 99, pp. 13459-13464.
11. 2 sensing. Science, 292, pp. 464-468.
12. 2-regulated prolyl hydroxylation. Science, 292, pp. 468-472.
13. Masson, N., Willam, C., Maxwell, PH, Pugh, CW and Ratcliffe, PJ (2001) Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J, 20, pp. 5197-5206.
14. White, SB, Zhao, Q. and Lee, FS (2001) HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A, 98, pp. 9630-9635.
15. Kamura, T., Maenaka, K., Kotoshiba, S., Matsumoto, M., Kohda, D., Conaway, RC, Conaway, JW and Nakayama, KI (2004) VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiqitin ligases. Genes Dev, 18, pp. 3055-3065.
16. Kaelin Jr, WG (2005) The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun, 338, pp. 627-638.
17. Constantinescu, SN, Ghaffari, S. and Lodish, HF (1999) The erythropoietin receptor: Structure, activation and intracellular signal transduction. TEM, 10, pp. 18-23.
18. Wormald, S. and Hilton, DJ (2004) Inhibitors of cytokine signal transduction. J Biol Chem, 279, pp. 821-824.
19. Gadina, M., Hilton, D., Johnston, JA, Morinobu, A., Lighvani, A., Zhou, Y-J, Visconti, R. and O'Shea, JJ (2001) Signaling by type I and II cytokines receptors: Ten years after. Curr Opin Immunol, 13, pp. 363-373.
20. Walrafen, P., Verdier, F., Kadri, Z., Chretien, S., Lacombe, C. and Mayeux, P. (2005) Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood, 105, pp. 600-608.
21. Sasaki, A., Yasukawa, H., Shouda, T., Kitamura, T., Dikic, I. and Yoshimura, A. (2000) CIS/SOCS-3 suppresses erythropoietin (Epo) signaling by binding the EPO receptor and JAK2. J Biol Chem, 275, pp. 29338-29347.
22. Schembri-King, J., Jakes, S. and Hayashi, J. (2000) Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J Immunol, 164, pp. 5199-5206.
23. Tong, W., Zhang, J. and Lodish, HF (2005) Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood, 105, pp. 4604-4612.
24. Juvonen, E., Ikkala, E., Fyhrquist, F. and Ruutu, T. (1991) Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood, 78, pp. 3066-3089.
25. de la Chapelle, A., Sistonen, P., Lehvaslaiho, H., Ikkala, E. and Juvonen, E. (1993) Familial erythrocytosis genetically linked to erythropoietin receptor gene. Lancet, 341, pp. 82-84.
26. de la Chapelle, A., Träskelin, A-L and Juvonen, E. (1993) Truncated erythropoietin receptor causes dominantly inherited human erythrocytosis. Proc Natl Acad Sci, 90, pp. 4495-4499.
27. Arcasoy, MO, Karayal, AF, Segal, HM, Sinning, JG and Forget, BG (2002) A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis. Blood, 99, pp. 3066-3069.
28. Petersen, BK, Hokland, P., Petersen, GB and Nyvold, CG (2004) Erythropoietin receptor defect: A cause of primary polycythaemia. Br J Haematol, 125, pp. 537-539.
29. Kralovics, R., Divoka, M., Stopka, T. and Prchal, JT (1997) Low frequency of erythropoietin receptor gene mutations in subjects with primary familial and congenital polycythemia. Blood, 90, p. 12a.
30. Kralovics, R., Sokol, L. and Prchal, JT (1998) Absence of polycythemia phenotype in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia. J Clin Path, 102, pp. 124-129.
31. Cario, H., Sola, S Rives, Neusuess, A., Kohne, E. and Schwarz, K. (2006) Molecular analyses in familial and sporadic congenital primary erythrocytosis. Haematologica, 91, pp. 352-353.
32. Kralovics, R., Indrak, K., Stopka, T., Berman, B., Prchal, JF and Prchal, JT (1997) Two new EPO receptor mutations: Truncated Epo receptors are most frequently associated with primary familial and congenital polycythemias. Blood, 90, pp. 2057-2061.
33. Watowich, SS, Xie, X., Klingmuller, U., Kere, J., Lindlof, M., Berglund, S. and de la Chapelle, A. (1999) Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state. Blood, 94, pp. 2530-2532.
34. Sokol, L., Luhovy, M., Guan, Y., Prchal, JF, Semenza, GL and Prchal, JT (1995) Primary familial polycythemia: Frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood, 86, pp. 15-22.
35. Arcasoy, MO, Degar, BA, Harris, KW and Forget, BG (1997) Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood, 89, pp. 4628-4635.
36. Furukawa, T., Narita, M., Sakaue, M., Otsuka, T., Kuroha, T., Masuko, M., Azegami, T., Kishi, K., Takahashi, M., Utsumi, J., Koike, T. and Aizawa, Y. (1997) Primary familial polycythaemia associated with a novel point mutation in the erythropoietin receptor. Br J Haematol, 99, pp. 222-227.
37. Percy, MJ, McMullin, MF, Roques, AWW, Westwood, NB, Acharya, J., Hughes, AE, Lappin, TRJ and Pearson, TC (1998) Erythrocytosis due to a mutation in the erythropoietin receptor gene. Br J Haematol, 100, pp. 407-410.
38. Couedic, J-P Le, Mitjavila, M-T, Villeval, J-L, Feger, F., Gobert, S., Mayeux, P., Casadevall, N. and Vainchenker, W. (1996) Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood, 87, pp. 1502-1511.
39. Sokol, L., Prchal, JF, D'Andrea, A., Rado, TA and Prchal, JT (1994) Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia. Exp Hematol, 22, pp. 447-453.
40. Kralovics, R., Sokol, L., Broxson Jr, EH and Prchal, JT (1997) The erythropoietin receptor gene is not linked with the polycythemia phenotype in a family with autosomal dominant primary polycythemia. Proc Assoc Am Physicians, 109, pp. 580-585.
41. Arcasoy, MO, Harris, KW and Forget, BG (1999) A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of JAK2 and Stat5 inactivation. Exp Hematol, 27, pp. 63-74.
42. Bourantas, LK, Chatzikyriakidou, A., Dasoula, A., Syrrou, M., Bourantas, KL and Georgiou, I. (2006) Absence of mutations of the EPO-receptor gene in Greek patients with familiar polycythemia. Eur J Haematol, 76, pp. 537-538.
43. Kralovics, R. and Prchal, JT (2001) Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol, 68, pp. 115-121.
44. Jedlickova, K., Stockton, DW and Prchal, JT (2003) Possible primary familial and congenital polycythemia locus at 7q22.1-7q22.2. Blood Cells Mol Dis, 31, pp. 327-331.
45. Baxter, JE, Scott, LM, Campbell, PJ, East, C., Fourouclas, N., Swanton, S., Vassiliou, GS, Bench, AJ, Boyd, EM, Curtin, N., Scott, MA, Erber, WN and Green, AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, pp. 1054-1061.
46. James, C., Ugo, V., Couedic, J-P Le, Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, JL, Constantinescu, SN, Casadevall, N. and Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, pp. 1144-1148.
47. Jones, AV, Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, AJ, Grand, FH, White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, EC, Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlmann, R., Hochhaus, A., Oscier, D., Silver, RT, Reiter, A. and Cross, NC (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 106, pp. 2158-2162.
48. Kralovics, R., Passamonti, F., Buser, AS, Teo, SS, Tiedt, R., Passweg, JR, Tichelli, A., Cazzola, M. and Skoda, RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Eng J Med, 352, pp. 1779-1790.
49. Lippert, E., Boissinot, M., Kralovics, R., Girodon, F., Dobo, I., Praloran, V., Boiret-Dupré, N., Skoda, RC and Hermouet, S. (2006) The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thromobcythemia and polycythemia vera. Blood, 108, pp. 1865-1867.
50. Rossi, D., Cortini, F., Deambrogi, C., Barbieri, C., Cerri, M., Franceschetti, S., Conconi, A., Capello, D. and Gaidano, G. (2007) Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera. Leuk Res, 31, pp. 97-101.
51. Percy, MJ, Jones, FGC, Green, AR, Reilly, JT and McMullin, MF (2006) The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica, 91, pp. 413-414.
52. Finazzi, G., Guerini, V., Ruggeri, M., Bernardi, M., Rambaldi, A., Rodeghiero, F. and Barbui, T. (2005) Low prevalence of JAK2 Val617Phe mutation in patients with idiopathic erythrocytosis. Blood, 106, p. 726a.
53. Verstovsek, S., Silver, RT, Cross, NCP and Tefferi, A. (2006) JAK2V617F mutational frequency in polycythemia vera: 100%, 90%, or less?. Leukemia, 211, p. 2067.
54. Sergeyeva, A., Gordeuk, VR, Tokarev, YN, Sokol, L., Prchal, JF and Prchal, JT (1997) Congenital polycythemia in Chuvashia. Blood, 89, pp. 2148-2154.
55. Ang, SO, Chen, H., Gordeuk, VR, Sergueeva, AI, Polyakova, LA, Miasnikova, GY, Kralovics, R., Stockton, DW and Prchal, JF (2002) Endemic polycythemia in Russia: Mutation in the VHL gene. Blood Cells Mol Dis, 28, pp. 57-62.
56. Ang, SO, Chen, H., Hirota, K., Gordeuk, VR, Jelinek, J., Guan, Y., Liu, E., Sergueeva, AI, Miasnikova, GY, Mole, D., Maxwell, PH, Stockton, DW, Semenza, GL and Prchal, JT (2002) Disruption of oxygen homeostatis underlies congenital Chuvash polycythemia. Nat Genet, 32, pp. 614-621.
57. Pastore, YD, Jelinek, J., Ang, S., Guan, Y., Lui, E., Jedlickova, K., Krishnamurti, L. and Prchal, JT (2003) Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood, 101, pp. 1591-1595.
58. Percy, MJ, McMullin, MF, Jowitt, SN, Potter, M., Treacy, M., Watson, WH and Lappin, TRJ (2003) Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. Blood, 102, pp. 1097-1099.
59. Pastore, YD, Jedlickova, K., Guan, Y., Lui, E., Fahner, J., Hasle, H., Prchal, JF and Prchal, JT (2003) Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet, 73, pp. 412-419.
60. Cario, H., Schwarz, K., Jorch, N., Kyank, U., Petrides, PE, Schneider, DT, Uhle, R., Debatin, K-M and Kohne, E. (2005) Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica, 90, pp. 19-24.
61. Bento, MC, Chang, K-T, Guan, Y., Liu, E., Caldas, G., Gatti, RA and Prchal, JF (2005) Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Landau gene: Five new Caucasian patients. Haematologica, 90, pp. 128-129.
62. Perrotta, S., Nobili, B., Ferraro, M., Migliaccio, C., Borriello, A., Cucciolla, V., Martinelli, V., Rossi, F., Punzo, F., Cirillo, P., Parisi, G., Zappia, V., Rotoli, B. and Della Ragiona, F. (2006) Von Hippel Lindau-dependent polycythemia is endemic on the island of Ischia: Identification of a novel cluster. Blood, 107, pp. 514-519.
63. Liu, E., Percy, MJ, Amos, CI, Guan, Y., Shete, S., Stockton, DW, McMullin, MF, Polyakova, LA, Ang, SO, Pastore, YD, Jedlickova, K., Lappin, TRJ, Gordeuk, V. and Prchal, JF (2004) The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood, 103, pp. 1937-1940.
64. Gordeuk, VR, Stockon, DW and Prchal, JT (2005) Congenital polycythemias/ erythrocytoses. Haematologica, 90, pp. 109-116.
65. Olschwang, S., Richard, S., Boisson, C., Giraud, S., Laurent-Puig, P., Resche, F. and Thomas, G. (1998) Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Human Mutation, 12, pp. 424-430.
66. Weirich, G., Klein, B., Wohl, T., Engelhardt, D. and Brauch, H. (2002) VHL2C phenotype is a German von Hippel-Lindau family with concurrent VHL germline mutations P81S and L188V. J Clin Endocrinol Metab, 87, pp. 5241-5246.
67. Clifford, SC, Cockman, ME, Smallwood, AC, Mole, DR, Woodward, ER, Maxwell, PH, Ratcliffe, PJ and Maher, ER (2001) Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet, 10, pp. 1029-1038.
68. Percy, MJ, Jones, FGC, Lappin, TRJ and McMullin, MF (2006) Diverse molecular defects associated with idiopathic erythrocytosis reflect the heterogeneity of this disorder. Haematologica, 91, pp. 209-210.
69. Randi, ML, Murgia, A., Putti, MC, Martella, M., Casarin, A., Opocher, G. and Fabris, F. (2005) Low frequency of VHL gene mutations in young individuals with polycythemia and high serum erythropoietin. Haeamtologica, 90, pp. 689-691.
70. Hon, W-C, Wilson, MI, Harlos, K., Claridge, TDW, Schofield, CJ, Pugh, CW, Maxwell, PH, Ratcliffe, PJ, Staurt, DI and Jones, EY (2002) Structural basis for the recognition of hydroxproline in HIF-1 by pVHL. Nature, 417, pp. 975-978.
71. Min, JH, Yang, H., Ivan, M., Gertler, F., Kaelin Jr, WG and Pavletich, NP (2002) Structure of an HIF-1alpha-pVHL complex: Hydroxyproline recognition in signaling. Science, 296, pp. 1886-1889.
72. Percy, MJ, Mooney, SM, McMullin, MF, Flores, A., Lappin, TRJ and Lee, FS (2003) A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1α (HIF-1α) does not impair Pro-564 hydroxylation. Mol Cancer, 2, pp. 31-37.
73. Fu, XS, Choi, E., Bubley, GJ and Balk, SP (2005) Identification of hypoxia-inducible factor-1alpha (HIF-1α) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate, 63, pp. 215-221.
74. Prior, SJ, Hagberg, JM, Phares, DA, Brown, MD, Fairfull, L., Ferrell, RE and Roth, SM (2003) Sequence variation in hypoxia-inducible factor 1alpha (HIF-1α): Association with maximal oxygen consumption. Physiol Genomics, 15, pp. 20-26.
75. Tanimoto, K., Yoshiga, K., Eguchi, H., Kaneyasu, M., Ukon, K., Kumazaki, T., Oue, N., Yasui, W., Imai, K., Nakachi, K., Poellinger, L. and Nishiyama, M. (2003) Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis, 24, pp. 1779-1783.
76. Yamada, N., Horikawa, Y., Oda, N., Iizuka, K., Shihara, N., Kishi, S. and Takeda, J. (2005) Genetic variation in the hypoxia-inducible factor-1 alpha gene is associated with type 2 diabetes in Japanese. J Clin Endocrinol Metab, 90, pp. 5841-5847.
77. Resar, JR, Roguin, A., Voner, J., Nasir, K., Hennebry, TA, Miller, JM, Ingersoll, R., Kasch, LM and Semenza, GL (2005) Hypoxia-inducible factor 1alpha polymorphism and coronary collaterals in patients with ischemic heart disease. Chest, 128, pp. 787-791.
78. 2-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha). J Cancer Res Clin Oncol, 128, pp. 358-362.
79. Percy, MJ, Zhao, Q., Flores, A., Harrison, C., Lappin, TR, Maxwell, PH, McMullin, MF and Lee, FS (2006) A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A, 103, pp. 654-659.
80. McDonough, MA, Flashman, E., Chowdhury, R., Mohr, C., Liénard, BMR, Zondlo, J., Oldham, NJ, Clifton, IJ, Lewis, J., McNeill, LA, Kurzeja, RJM, Hewitson, KS, Yang, E., Jordan, S., Syed, RS and Schofield, CJ (2006) Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci U S A, 103, pp. 9814-9819.
81. Taylor, MS (2001) Characterization and comparative analysis of the ELGN gene family. Gene, 275, pp. 125-132.
82. Whaley, JM, Naglich, J., Gelbert, L., Hsia, YE, Lamiell, JM, Green, JS, Collins, D., Neumann, HP, Laidlaw, J. and Li, FP (1994) Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet, 55, pp. 1092-1102.
83. Gordeuk, VR, Sergueeva, AI, Miasnikova, GY, Okhotin, D., Voloshin, Y., Choyke, PL, Butman, JA, Jedlickova, K., Prchal, JT and Polyakova, LA (2004) Congenital disorder of oxygen sensing: Association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood, 103, pp. 3924-3932.
84. Smith, TG, Brooks, JT, Balanos, GM, Lappin, TR, Layton, DM, Leedham, DL, Liu, C., Maxwell, PH, McMullin, MF, McNamara, CJ, Percy, MJ, Pugh, CW, Ratcliffe, PJ, Talbot, NP, Treacy, M. and Robbins, PA (2006) Mutation of von Hippel-Lindau tumor suppressor and human cardiopulmonary physiology. PLoS Med, 3, pp. 1178-1186.
85. Rathmell, WK, Hickey, MM, Bezman, NA, Chmielecki, CA, Carrawary, NC and Simon, MC (2004) In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res, 64, pp. 8595-8603.
86. Kato, H., Inoue, T., Asanoma, K., Nishimura, C., Matsuda, T. and Wake, N. (2006) Induction of human endometrial cancer cell senescence through modulation of HIF-1α activity by EGLN1. Int J Cancer, 118, pp. 1144-1153.
87. Lee, FS, Percy, MJ and McMullin, MF (2006) Oxygen sensing: Recent insights from idiopathic erythrocytosis. Cell Cycle, 5, pp. 941-945.